IRB #

STUDY00016896

Title

A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients
with Advanced Malignancies

Principal Investigator

Elie Traer

Study Purpose

This study is being done to test the good and bad effects of DCC-3014-01-001 in patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, and Chronic Lymphoblastic Leukemia.

Medical Condition(s)

Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Chronic Lymphoblastic Leukemia (CLL)

Eligibility Criteria

1. Men and women 18 years or older, except for patients with ALL who can be 16 years or older
2. Have been diagnosed with AML, MDS, ALL, or CLL, and your disease has not responded to previous treatment
3. Adequate organ function
4. Other criteria apply

Age Range

16 - n/a

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. 30 days after last dose of study drug, participants will have a follow-up visit.

Minors Included

Yes

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Deciphera Pharmaceuticals, LLC

Recruitment End

05/31/2019

Compensation Provided

No


Go Back